NASDAQ:AMRS - Amyris Stock Price, Forecast & News

Amyris' stock was trading at $2.96 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AMRS stock has decreased by 23.0% and is now trading at $2.28. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amyris.

Amyris is scheduled to release its next quarterly earnings announcement on Monday, October 5th 2020. View our earnings forecast for Amyris.

Amyris Inc (NASDAQ:AMRS) released its quarterly earnings results on Thursday, March, 12th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.42. The biotechnology company earned $40.54 million during the quarter, compared to analyst estimates of $47 million. View Amyris' earnings history.

Amyris's stock reverse split before market open on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

2 Wall Street analysts have issued 12 month price targets for Amyris' shares. Their forecasts range from $8.00 to $11.00. On average, they expect Amyris' share price to reach $9.50 in the next year. This suggests a possible upside of 316.7% from the stock's current price. View analysts' price targets for Amyris.

Press coverage about AMRS stock has been trending somewhat positive this week, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amyris earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutAmyris.

Some companies that are related to Amyris include Phillips 66 (PSX), Valero Energy (VLO), Marathon Petroleum (MPC), HollyFrontier (HFC), CVR Energy (CVI), World Fuel Services (INT), Delek US (DK), PBF Energy (PBF), Renewable Energy Group (REGI), Clean Energy Fuels (CLNE), REX American Resources (REX), Green Plains (GPRE), Adams Resources & Energy (AE) and Gevo (GEVO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Gevo (GEVO), Keryx Biopharmaceuticals (KERX), Novavax (NVAX), Canopy Growth (CGC), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Intel (INTC), MEI Pharma (MEIP), General Electric (GE) and Amarin (AMRN).

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Amyris' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (8.01%), Pinnacle Associates Ltd. (1.29%), State Street Corp (0.83%), Geode Capital Management LLC (0.65%), Essex Investment Management Co. LLC (0.42%) and Goldman Sachs Group Inc. (0.29%). Company insiders that own Amyris stock include (Mauritius) Pte Ltd Maxwell, Eduardo Alvarez, Frank Kung, John Melo, Kathleen Valiasek, L John Doerr and Patrick Y Yang. View institutional ownership trends for Amyris.

AMRS stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Goldman Sachs Group Inc., Principal Financial Group Inc., Alliancebernstein L.P., Bank of America Corp DE, and Rice Hall James & Associates LLC. Company insiders that have sold Amyris company stock in the last year include John Melo, and Patrick Y Yang. View insider buying and selling activity for Amyris.

AMRS stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Pinnacle Associates Ltd., Essex Investment Management Co. LLC, State Street Corp, Geode Capital Management LLC, Spark Investment Management LLC, Virtus ETF Advisers LLC, and Levin Capital Strategies L.P.. Company insiders that have bought Amyris stock in the last two years include Eduardo Alvarez, Frank Kung, Kathleen Valiasek, L John Doerr, and Patrick Y Yang. View insider buying and selling activity for Amyris.

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMRS stock can currently be purchased for approximately $2.28.

Amyris has a market capitalization of $373.56 million and generates $152.56 million in revenue each year. The biotechnology company earns $-242,770,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. Amyris employs 414 workers across the globe. View additional information about Amyris.

The official website for Amyris is http://amyris.com/.

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]